Seltzer Justin, Hardin Jeremy, Galust Henrik, Friedman Nathan, Corbett Bryan, Clark Richard F
Division of Medical Toxicology, Department of Emergency Medicine, UC San Diego Health, CA, USA.
VA San Diego Healthcare System, San Diego, CA, USA.
Toxicol Rep. 2024 May 15;12:574-577. doi: 10.1016/j.toxrep.2024.05.007. eCollection 2024 Jun.
Phenobarbital is a long-acting barbiturate used to treat alcohol withdrawal and epilepsy. Acute overdoses present with varying levels of central nervous system depression and large overdoses can be life threatening. Phenobarbital is an attractive candidate for enhanced elimination using urinary alkalinization given it is a weak acid with a long half-life and extensive urinary elimination. Limited human data exist regarding use of urine alkalinization for the treatment of phenobarbital overdose. We present a fourteen-year-old female who was treated with urinary alkalinization alone following an intentional ingestion of 3800 mg (84.4 mg/kg) of phenobarbital tablets. Urine drugs of abuse screening was preliminary positive for barbiturates and confirmed to be phenobarbital only. The initial serum phenobarbital concentration, drawn nine hours post-ingestion, was 97.4 mcg/ml (normal range 15-40 mcg/ml). Urinary alkalinization with sodium bicarbonate was started approximately 12 h post-ingestion and stopped at 72 h post-ingestion; clinical toxicity resolved by hospital day 5. The infusion was titrated to a urinary pH of greater than 7.5. Serial serum and urine phenobarbital measurements were obtained to determine elimination half-life and urinary excretion. The elimination half-life while undergoing urinary alkalinization was 81.3 h. Prior to initiation of urinary alkalinization, the urine phenobarbital concentration was 37 mcg/ml. Approximately 8.75 h after initiation, it was greater than 200 mcg/ml at a urine pH of 8.5. Urinary alkalinization appeared to augment urinary phenobarbital excretion, though with no discernible effect on elimination half-life and unclear clinical benefit. Further research is needed to better characterize the clinical effects of urinary alkalinization for phenobarbital overdose.
苯巴比妥是一种长效巴比妥类药物,用于治疗酒精戒断和癫痫。急性过量服用会导致不同程度的中枢神经系统抑制,大量过量服用可能危及生命。鉴于苯巴比妥是一种半衰期长且经尿液大量排泄的弱酸,它是通过尿液碱化来加强清除的理想药物。关于使用尿液碱化治疗苯巴比妥过量的人体数据有限。我们报告一名14岁女性,她在故意摄入3800毫克(84.4毫克/千克)苯巴比妥片后仅接受了尿液碱化治疗。滥用药物尿液筛查初步显示巴比妥类药物呈阳性,随后证实仅为苯巴比妥。摄入后9小时测得的初始血清苯巴比妥浓度为97.4微克/毫升(正常范围15 - 40微克/毫升)。摄入后约12小时开始用碳酸氢钠进行尿液碱化,并在摄入后72小时停止;临床毒性在住院第5天时消退。输注量调整至尿液pH值大于7.5。连续进行血清和尿液苯巴比妥测量以确定消除半衰期和尿排泄情况。尿液碱化期间的消除半衰期为81.3小时。在开始尿液碱化之前,尿液苯巴比妥浓度为37微克/毫升。开始后约8.75小时,在尿液pH值为8.5时,其浓度大于200微克/毫升。尿液碱化似乎增加了尿液中苯巴比妥的排泄,尽管对消除半衰期没有明显影响,且临床益处尚不清楚。需要进一步研究以更好地描述尿液碱化治疗苯巴比妥过量的临床效果。